Patents Assigned to HANSA BIOPHARMA AB
  • Patent number: 12359183
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: July 15, 2025
    Assignee: Hansa Biopharma AB
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Andersson Nordahl
  • Publication number: 20230210962
    Abstract: The present invention relates to a conditioning regimen for the transplant of a cell, tissue or organ, optionally hematopoietic stem / progenitor cells, to a subject. The invention also relates to methods for the induction of hematopoietic chimerism in a subject. The invention also relates to methods for the prevention or treatment of a disease or condition in a subject, in which hematopoietic chimerism is induced in order to improve the benefit to the subject of a subsequent therapy. The subsequent therapy may be a cell, tissue or organ transplant or may a gene therapy administered using genetically modified hematopoietic stem cells/progenitor cells.
    Type: Application
    Filed: March 3, 2021
    Publication date: July 6, 2023
    Applicant: Hansa Biopharma AB
    Inventors: Robert Bockermann, Anna-Karin Louise Robertson, Jiaxin LIN, Colin Charles ANDERSON
  • Publication number: 20230181701
    Abstract: The present invention relates to methods for enhancing adoptive cell transfer immunotherapy by administering a protein that has IgG cysteine protease or IgG endoglycosidase activity.
    Type: Application
    Filed: May 18, 2021
    Publication date: June 15, 2023
    Applicant: Hansa Biopharma AB
    Inventor: Christian Kjellman
  • Patent number: 11667905
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: June 6, 2023
    Assignee: HANSA BIOPHARMA AB
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • Publication number: 20230110085
    Abstract: The present invention relates to improved methods for detecting immunoglobulin M (IgM), immunoglobulin A (IgA) and immunoglobulin E (IgE) antibodies, and new therapies for diseases and conditions mediated by pathogenic antibodies and antibody complexes.
    Type: Application
    Filed: February 12, 2021
    Publication date: April 13, 2023
    Applicant: Hansa Biopharma AB
    Inventors: Anna RUNSTRÖM, Robert BOCKERMANN, Kristoffe SJÖHOLM, Markus ROUPÉ, Christian KJELLMAN, Tomas LORANT
  • Patent number: 11214784
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: January 4, 2022
    Assignee: Hansa BioPharma AB
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • Patent number: 10758597
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: September 1, 2020
    Assignee: HANSA BIOPHARMA AB
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • Patent number: 10696959
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 30, 2020
    Assignee: HANSA BIOPHARMA AB
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl